ライフサイエンスコーパス: CNS lymphoma

1 tients aged 70 years or younger with primary CNS lymphoma.

2 SCT in patients with newly diagnosed primary CNS lymphoma.

3 mosis medications alone, and one patient had CNS lymphoma.

4 ell transplantation in patients with primary CNS lymphoma.

5 ssessment, staging, and treatment of primary CNS lymphoma.

6 ines for immunocompetent adults with primary CNS lymphoma.

7 ation, and tissue biopsy in the diagnosis of CNS lymphoma.

8 ore than 95% specificity in the diagnosis of CNS lymphoma.

9 ent of patients with newly diagnosed primary CNS lymphoma.

10 aseline risk evaluation in untreated primary CNS lymphoma.

11 6.1% in human immunodeficiency virus-related CNS lymphoma.

12 le and active in the treatment of refractory CNS lymphoma.

13 )F-FDG PET as a prognostic marker in primary CNS lymphoma.

14 resurgical evaluation for cases of suspected CNS lymphoma.

15 iotherapy (rdWBRT) and cytarabine in primary CNS lymphoma.

16 le and active in the treatment of refractory CNS lymphoma.

17 t may contribute to the pathogenesis of this CNS lymphoma.

18 role for JCV in the pathogenesis of primary CNS lymphoma.

19 l nervous system (CNS) and is called primary CNS lymphoma.

20 s-positive control tissues including several CNS lymphomas.

21 atistically significant (P = 0.011) in these CNS lymphomas.

22 mor vasculature as well as by tumor cells in CNS lymphomas.

23 ling, by tumor cells and tumor endothelia in CNS lymphomas.

24 specimens of primary central nervous system (CNS) lymphomas (12/27 [44.4%]), an EBV-associated malign

25 -5.2%]; BL, 21.5% [95% CI, 17.7%-25.4%]; and CNS lymphoma, 12.9% [95% CI, 10.5%-15.3%]; all P < .001

26 10.5%]; BL, 27.8% [95% CI, 25.0%-30.5%]; and CNS lymphoma, 48.3% [95% CI, 46.7%-49.8%]; all P < .001

27 The pathogenesis of CNS lymphomas affects multiple compartments within the n

28 ed 18-70 years) with newly diagnosed primary CNS lymphoma and an Eastern Cooperative Oncology Group p

29 up to 70 years with newly diagnosed primary CNS lymphoma and as the control group for future randomi

30 gates of prognosis and treatment response in CNS lymphoma and brain metastasis.

31 and identify several hundred CSF proteins in CNS lymphoma and control patients.

32 ged 18-65 years with newly diagnosed primary CNS lymphoma and immunocompetence, with no limitation on

33 ed 18-70 years) with newly diagnosed primary CNS lymphoma and measurable disease were enrolled from 5

34 c method for rapid differential diagnosis of CNS lymphoma and toxoplasmosis in patients with AIDS.

35 ith high doses of antimetabolites in primary CNS lymphoma and with rituximab plus high-dose sequentia

36 e elucidation of the molecular properties of CNS lymphomas and their microenvironment, as well as evo

37 rent knowledge regarding the pathogenesis of CNS lymphomas and to highlight promising strategies that

38 diagnosis of primary central nervous system (CNS) lymphoma and cerebral toxoplasmosis in patients wit

39 terleukin (IL)-10 in central nervous system (CNS) lymphomas and to evaluate the utility of each as pr

40 t lymphoma [BL], and central nervous system [CNS] lymphoma), and cervical cancer.

41 tients age 18 to 70 years old with secondary CNS lymphoma, and we propose it as a new standard therap

42 ATIII RNA transcripts were identified within CNS lymphomas, and ATIII protein was localized selective

43 rends of CNS malignancies, including primary CNS lymphomas, and on survival probability.

44 , such as glioblastoma multiforme or primary CNS lymphomas, are less common.

45 ial addressing a new treatment for secondary CNS lymphoma based on encouraging experiences with high

46 young patients with newly diagnosed primary CNS lymphoma, but further comparative studies are needed

47 e-based chemotherapy is standard for primary CNS lymphoma, but most patients relapse.

48 Central nervous system (CNS) lymphoma can present a diagnostic challenge.

49 cases, 27.1% (95% CI, 26.1%-28.1%) of 27,265 CNS lymphoma cases, and 0.42% (95% CI, 0.37%-0.47%) of 3

50 s [immunoblastic and central nervous system (CNS) lymphoma] caused by loss of T-cell function, and (2

51 is and other neurological syndromes and with CNS lymphomas (CNSLs).

52 Recurrent CNS lymphoma continues to be associated with poor outcom

53 trexate (MTX)-based chemotherapy for primary CNS lymphoma, determine whether additional cycles of ind

54 We conducted a review of the literature on CNS lymphoma diagnosis (1966 to October 2011) to determi

55 Although a CNS lymphoma diagnosis was once assumed to be uniformly

56 sis that individual CSF proteins distinguish CNS lymphoma from benign focal brain lesions.

57 retention index is useful in differentiating CNS lymphomas from other malignant and nonmalignant path

58 can help distinguish central nervous system (CNS) lymphoma from toxoplasmosis and other nonmalignant

59 s and their contribution to the diagnosis of CNS lymphoma in 91 diffuse large B-cell lymphomas (DLBCL

60 ymptoms in DLBCL and BL and with parenchymal CNS lymphoma in DLBCL; sCD19 emerged as a powerful predi

61 n normal, thus explaining the propensity for CNS lymphomas in AIDS.

62 When primary CNS lymphoma initially involves the retina, it is named

63 Primary CNS lymphoma is an aggressive form of non-Hodgkin lympho

64 The management of primary CNS lymphoma is one of the most controversial topics in

65 Primary central nervous system (CNS) lymphoma is an aggressive non-Hodgkin lymphoma with

66 Primary central nervous system (CNS) lymphoma is an unusual but increasingly frequent br

67 e chemotaxis of lymphoma cells isolated from CNS lymphoma lesions.

68 show that while individual cases of primary CNS lymphomas may be classified as germinal center B-cel

69 scale, or MILAS) was used to assess primary CNS lymphoma metabolism as a marker of clinical aggressi

70 We also identify high expression in CNS lymphomas of several IL-4-induced genes, including X

71 n the neuroaxis, and proper treatment of the CNS lymphoma patient requires a multidisciplinary team w

72 concentration of CXCL13 and IL-10 in CSF of CNS lymphoma patients and control cohorts including infl

73 ssibly a cure, for a significant fraction of CNS lymphoma patients.

74 AIDS subjects, including those with primary CNS lymphoma (PCNSL) (outside the area of neoplastic inv

75 Primary CNS lymphoma (PCNSL) and primary intraocular lymphoma (I

76 valuation and response assessment of primary CNS lymphoma (PCNSL) are critical to ensure comparabilit

77 Primary CNS lymphoma (PCNSL) harbors mutations that reinforce B

78 rs for patients with newly diagnosed primary CNS lymphoma (PCNSL) in order to establish a predictive

79 Primary CNS lymphoma (PCNSL) is a rare form of extranodal non-Ho

80 Primary CNS lymphoma (PCNSL) is an aggressive lymphoma but clini

81 Primary CNS lymphoma (PCNSL) is an aggressive primary brain tumo

82 PURPOSE Primary CNS lymphoma (PCNSL) is confined to the CNS and/or the e

83 viously reported on 31 patients with primary CNS lymphoma (PCNSL) treated between 1986 and 1992 with

84 Four patients with recurrent primary CNS lymphoma (PCNSL) were studied.

85 Primary CNS lymphoma (PCNSL), an uncommon form of extranodal non

86 ation therapy (RT) for patients with primary CNS lymphoma (PCNSL).

87 patients with relapsed or refractory primary CNS lymphoma (PCNSL).

88 eutic strategies as consolidation in primary CNS lymphoma (PCNSL).

89 d initial high-dose methotrexate for primary CNS lymphoma (PCNSL).

90 ontrol and survival in patients with primary CNS lymphoma (PCNSL).

91 Primary central nervous system (CNS) lymphoma (PCNSL) and primary testicular lymphoma (P

92 Primary central nervous system (CNS) lymphoma (PCNSL) is a diffuse large B-cell lymphoma

93 rimary and secondary central nervous system (CNS) lymphoma poses a unique set of diagnostic, prognost

94 aventricular rituximab/MTX, including 1 with CNS lymphoma refractory to high-dose systemic and intrat

95 Optimum treatment for patients with primary CNS lymphoma remains challenging because there have not

96 Standard treatment for patients with primary CNS lymphoma remains to be defined.

97 (MZBCL) is the most common primary low-grade CNS lymphoma reported in the literature.

98 IL-10 as potentially important biomarkers of CNS lymphoma that merit further evaluation and support i

99 at intracranial MZBCL is an indolent primary CNS lymphoma that typically presents as a meningioma-lik

100 any Radiation Therapy Oncology Group primary CNS lymphoma trial.

101 in newly diagnosed non-AIDS-related primary CNS lymphoma was conducted in the New Approaches to Brai

102 petent patients with newly diagnosed primary CNS lymphoma who underwent pretreatment (18)F-FDG PET we

103 an independent set of patients with primary CNS lymphoma who were treated with high-dose intravenous

104 t modality was effective against established CNS lymphoma with leptomeningeal metastases, sites that

105 study investigated the treatment of primary CNS lymphoma with methotrexate, temozolomide (TMZ), and

106 are the gene expression signature of primary CNS lymphomas with nodal large B-cell lymphomas.

107 was 99.3% specific for primary and secondary CNS lymphoma, with sensitivity significantly greater tha